|Idiopathic Pulmonary Fibrosis Patients to Have Expanded Access to Therapy|
CPF Responds to InterMune’s Launch of an Expanded Access Program for Pirfenidone
For the first time in history, people suffering from the deadly lung disease idiopathic pulmonary fibrosis (IPF) will have access to a therapy. The Coalition for Pulmonary Fibrosis (CPF) commends the steps taken by the company, InterMune, Inc., to provide an Expanded Access Program (EAP) for the investigational drug, pirfenidone. The CPF represents thousands of patients suffering from the disease in the US that claims as many lives each year as breast cancer yet has limited awareness and recognition.
InterMune, Inc. announced today that the company will implement an EAP for pirfenidone. The EAP will be conducted under a treatment protocol limited to enrollment of IPF patients in the US who meet specific medical criteria.
To enroll in the EAP, a patient must be assessed by a physician who specializes in treating IPF and whose hospital or clinic center is participating in the EAP. The patient must also meet specific eligibility requirements. This means that not all physicians can provide access to pirfenidone through the EAP and not all patients who seek pirfenidone will be able to get access to it through EAP.
CPF encourages its patients with IPF to inquire about the EAP by calling InterMune Medical Information at 1-888-486-6411.
“The CPF is grateful to InterMune for its long-term commitment to the search for a PF treatment, and its willingness to extend the opportunity to access pirfenidone to an additional cohort of those who meet the enrollment requirements,” said Mishka Michon, CEO of the CPF.
About Pulmonary Fibrosis (PF)
About the CPF